title: Cutaneous myeloid sarcoma presenting as grey pigmented macules.
authors.forename: Shiro
authors.initials: S
authors.lastname: Niiyama
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Amoh
authors.forename: Akira
authors.initials: A
authors.lastname: Watarai
authors.forename: Kensei
authors.initials: K
authors.lastname: Katsuoka
authors.forename: Hideki
authors.initials: H
authors.lastname: Mukai
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000032:analysis; D002891:Chromosomes, Human, Pair 21; D002897:Chromosomes, Human, Pair 7; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D008297:Male; D023981:Sarcoma, Myeloid / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D012880:Skin Pigmentation; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine